SCHEMBL97159

SCHEMBL97159

[CH2]c1ccc(NS(=O)(=O)c2cc(F)c(F)cc2F)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 5/20 0.44
PTK2B Q14289 1/20 0.44
SLC22A12 Q96S37 2/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HTT P42858 2/20 0.42
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
IDH1 O75874 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 2/20 0.38
GFER P55789 2/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALPL P05186 1/20 0.38
MOGAT2 Q3SYC2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95455 0.83 SGK1 (0.52) SGK1PTK2BHTTHPGDNPSR1
SCHEMBL97723 0.83 POLB (0.50) ALDH1A1HTTHPGDNPSR1SMN1; SMN2
SCHEMBL95946 0.81 NMT1 (0.52) CA1CA2ALDH1A1HTTSMN1; SMN2
SCHEMBL97052 0.79 ALDH1A1 (0.65) SGK1PTK2BSLC22A12ALDH1A1GAA
SCHEMBL6680003 0.79 LMNA (0.58) SGK1CA1CA2ALDH1A1HTT
SCHEMBL96374 0.78 LMNA (0.59) CA1CA2ALDH1A1HTTHPGD
SCHEMBL95834 0.74 BRD4 (0.51) SGK1CA1CA2HTTHPGD
SCHEMBL95548 0.74 HTT (0.55) ALDH1A1HTTHPGDNPSR1IDH1
SCHEMBL96565 0.74 PKM (0.66) CA1CA2ALDH1A1GAAGFER
SCHEMBL7536270 0.73 LMNA (0.56) SGK1ALDH1A1HTTHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB SGK1 494/4885PTK2B 138/4885SLC22A12 3575/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 SGK1 845/4885PTK2B 259/4885SLC22A12 2298/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 SGK1 845/4885PTK2B 259/4885SLC22A12 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.